United States

Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

1 Apr 2015
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo announces outcome of arbitration proceeding with Ranbaxy
Friday, 6 May 2016 03:55am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Says Daiichi Sankyo received a final award in the arbitration that it filed with the International Court of Arbitration of the International Chamber of Commerce in November 2012 against the former shareholders Ranbaxy Laboratories Ltd.[RANB.NS] on May 3 . Says they filed Ranbaxy concealed and misrepresented certain critical information concerning US Food and Drug Administration and Department of Justice investigations at the time of Daiichi Sankyo’s purchase of shares of Ranbaxy . Says Ranbaxy to pay Daiichi Sankyo 25.63 billion Indian rupees as compensatory damages and 8.51 billion Indian rupees as interest .Says Ranbaxy to pay Daiichi Sankyo $14.5 million for attorneys’ fees and expenses and $599,250 for arbitration costs which were incurred by Daiichi Sankyo.  Full Article

Ranbaxy Laboratories Ltd - Sun Pharmaceutical Industries Ltd recalls anti-allergic drug in US - Times of India
Tuesday, 27 Oct 2015 10:33pm EDT 

Ranbaxy Laboratories Ltd:Sun Pharma has initiated a recall of over a million packs of anti-allergic Loratadine drug from the US market after checks reportedly revealed the tablets were 'super potent' and 'out of specification' - Times of India.Loratadine tablets are manufactured and distributed in the US market by Ohm Laboratories, US-based subsidiary of Ranbaxy. Loratadine is generic version of Bayer's Claritin drug - Times of India.Sun Pharma acquired Ranbaxy in a $4 billion deal in April 2014, making it the largest domestic pharma company by sales - Times of India.  Full Article

Ranbaxy settles 'pay-for-delay' case ahead of jury deliberations

Generic drugmaker Ranbaxy Laboratories has agreed to settle lawsuits accusing it of accepting payments from pharmaceutical company Cephalon Inc to delay the release of a generic version of the latter's wakefulness drug Provigil.